Allogene Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. Founded in 2017 and headquartered in South San Francisco, California, the company pioneers off-the-shelf CAR T products derived from healthy donor T cells, featuring multiplex gene-engineering, gene-editing, proprietary lymphodepletion platforms, and state-of-the-art manufacturing to enable scalable access, speed, reliability, and innovation beyond autologous therapies. Its lead product candidate, cemacabtagene ansegedleucel (cema-cel), advances in the pivotal Phase 2 ALPHA3 trial as frontline consolidation therapy for large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), targeting minimal residual disease with potential MRD conversion and first data readout expected in the first half of 2026; ALLO-316 targets clear cell renal cell carcinoma (ccRCC) in the TRAVERSE trial, which completed Phase 1b enrollment in heavily pretreated patients and secured FDA alignment on a pivotal path forward, positioning it as the only allogeneic CAR T showing clinically meaningful responses in metastatic solid tumors; ALLO-329, a CD19/CD70 dual-targeting CAR with Dagger technology to potentially reduce lymphodepletion needs, enrolls in the Phase 1 RESOLUTION trial for autoimmune diseases. The company operates primarily in the United States with research and development in South San Francisco and manufacturing in Newark, California, while conducting multi-center clinical trials potentially spanning North America and Europe, supported by strategic collaborations including Pfizer, Servier, Cellectis, Regeneron, Takeda, and GSK that provide milestone payments up to billions. Recent developments include Q3 2025 financial results showing a net loss of $41.4 million on $44.9 million operating expenses, cash reserves of $277.1 million extending into late 2027, ongoing ALPHA3 patient identification and site best practices for LBCL consolidation, TRAVERSE Phase 1b completion for ALLO-316 with partnership potential, and RESOLUTION enrollment initiation for ALLO-329 in autoimmune indications, reflecting disciplined execution amid a streamlined 2025 cash burn target of approximately $170 million.
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 13.1% After Analyst Upgrade
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock